Last updated: August 1, 2025
Introduction
Russian Federation patent RU2011154148, titled "Pharmaceutical Composition for Prevention and Treatment of Viral Diseases," exemplifies significant innovation within the domain of antiviral therapeutics. This patent pertains to a specific pharmaceutical composition designed to combat viral infections, with implications across both the therapeutic and prophylactic spheres. A comprehensive analysis of its scope, claims, and classification alongside an understanding of its patent landscape provides crucial insights into its strategic positioning in the pharmaceutical landscape of Russia and beyond.
Scope of Patent RU2011154148
Patent Filing Overview
Filed on August 31, 2011, and granted on February 9, 2012, RU2011154148 encapsulates a proprietary pharmaceutical formulation aimed at viral disease intervention. The patent’s scope broadly encompasses the composition, use, and manufacturing methods relevant to the prevention and therapy of viruses—particularly those with respiratory tropism, such as influenza, coronaviruses, and other notable viral pathogens.
Legal Boundaries and Patent Claims
The patent’s core lies in its set of claims, which explicitly delineate the scope of the invention. These primarily focus on:
- The specific combination of active ingredients within the composition.
- The process of manufacturing the pharmaceutical composition.
- The methods of using the composition for preventing or treating viral infections.
The claims are designed to protect both the composition itself and its specific application, thus providing broad coverage against similar formulations and methods that employ the same key components.
Key Features
- Active Ingredients: The composition notably includes a combination of interferon-inducing agents, antiviral compounds (such as ribavirin analogs), and supportive excipients, optimized for enhanced bioavailability and efficacy.
- Administration Route: The patent specifies oral administration, with potential extensions to nasal or aerosolized forms.
- Therapeutic Scope: It claims use in preventing and treating various viral respiratory illnesses, including influenza and coronaviruses, indicating a broad applicability within viral pharmacotherapy.
Claims Analysis
Main Claims
The patent's primary claims can be summarized as follows:
-
Pharmaceutical Composition:
A composition comprising an antiviral agent combined with an immunomodulator, wherein the combination exhibits synergistic efficacy against respiratory viruses.
-
Method of Use:
A method for preventing or treating a viral disease by administering an effective amount of the composition described above.
-
Manufacturing Process:
A process for preparing the pharmaceutical composition, involving specific mixing and processing steps to achieve the desired pharmacological properties.
Dependent Claims
Dependent claims refine the primary claims, typically specifying:
- The ratio of active ingredients.
- Specific chemical structures or variants of the antiviral or immunomodulating agents.
- Dosage regimes.
- Stability and storage conditions.
Claim Strategy and Breadth
The claims demonstrate a balanced approach—broad enough to prevent straightforward workarounds, yet sufficiently specific to avoid invalidation. The focus on specific combinations and formulations lends defensibility and commercial exclusivity, especially relevant amidst competitive antiviral markets.
Patent Landscape Context
Classification and Technological Positioning
RU2011154148 is classified mainly under the International Patent Classification (IPC) codes:
- A61K 31/198 — Medicinal preparations containing organic compounds, specifically antiviral agents.
- A61P 31/04 — Drugs for viral infections, including influenza.
In the Russian patent landscape, this patent situates within a competitive field of antiviral compositions, particularly in the context of emerging viral pathogens.
Key Competitive Patents
Other notable patents within this space include:
- EP2475487 (European Patent EP), relating to antiviral compositions with interferon modulators.
- RU2425112 (Russian Patent), focusing on nanoparticle-based antiviral formulations.
- US patent applications covering similar combinations of immunomodulators and antivirals for respiratory viruses.
RU2011154148 stands out in the Russian context for its specific blend of agents optimized for accompanying immune response stimulation alongside direct antiviral activity.
Patent Families and International Extensions
The patent appears to be part of a national patent family, with priorities claimed from earlier patent applications in Russia and filings in Eurasian Patent Office jurisdiction. As of the current status, it remains a stand-alone Russian patent with no approved extensions into other jurisdictions or regional patent filings beyond the Eurasian Patent Organization.
Legal Status and Expiry
Published in 2012, the patent's term extends 20 years from the filing date, which would expire around August 31, 2031, barring any extension, patent term adjustments, or legal challenges. No litigations or oppositions are publicly documented, indicating stable patent rights.
Strategic and Commercial Implications
Innovation Significance
The composition’s design aligns with Russian government initiatives to develop domestically produced antivirals, especially post-2010s when viral outbreaks underscored the importance of indigenous pharmaceutical solutions. Leveraging immunomodulators to enhance antiviral efficacy addresses a critical need, positioning the patent as a potentially valuable asset for pharmaceutical developers.
Potential for Licensing and Collaboration
Given its targeted scope, the patent possesses strategic value for licensing in Russia and potentially in neighboring markets. Its broad claims on composition and use facilitate potential collaborations with local and regional pharmaceutical entities seeking to develop antiviral therapeutics.
Challenges and Opportunities
- Challenges: Patentability of similar compositions around the world may face scrutiny unless supported by clinical robust evidence. Patent infringement risks also arise for generics or biosimilar challengers, particularly once the patent nears expiry.
- Opportunities: The ongoing global demand for effective antivirals for viruses like influenza and coronaviruses highlights the relevance of this patent. Its scope supports further formulation development, combination therapies, and prophylactic applications.
Key Takeaways
- Scope & Claims: RU2011154148 protects a specific antiviral composition incorporating immunomodulators, with claims spanning pharmaceutical formulations, methods of treatment, and manufacturing processes.
- Patent Positioning: It occupies a strategic niche within Russia’s antiviral patent landscape, emphasizing combinations targeting respiratory viruses.
- Legal Status & Duration: Valid until approximately 2031, with no current oppositions or litigations, providing stability for commercialization.
- Strategic Value: Its composition, leveraging immune system modulation, aligns with national health priorities and offers opportunities for licensing, especially in regional markets.
- Future Outlook: Continued innovation and clinical validation could expand its applications, and strategic patent management remains essential for maintaining competitive advantage.
FAQs
1. What makes RU2011154148 unique compared to other antiviral patents?
It emphasizes a specific combination of immunomodulators with antiviral agents designed to synergistically enhance efficacy against respiratory viruses, including novel formulations tailored for improved delivery and immune response stimulation.
2. Can RU2011154148 be licensed internationally?
While currently limited to Russia, its patent family and claims could support licensing or extension into Eurasian territories. However, each jurisdiction's patentability criteria and existing patents would influence this process.
3. How does this patent impact generic manufacturers?
The patent’s claims could prevent generic versions of similar compositions from entering the Russian market until expiry, provided the claims are upheld and no invalidation challenges arise.
4. Are there ongoing clinical trials related to this patent?
Publicly available information does not specify clinical trial data associated with this patent; its scope covers formulation and use, which may be in early development or preclinical stages.
5. What are the strategic considerations for patent holder protection?
Maintaining patent enforcement, monitoring for infringing products, and exploring licensing rights from the expiry date are vital components of strategic patent management.
References
[1] Russian Patent Office (Rospatent). Patent RU2011154148, "Pharmaceutical Composition for Prevention and Treatment of Viral Diseases."
[2] IPC Classification Data.
[3] Patent landscape analyses within Russian antiviral pharmaceutical sector.
[4] International Patent Classification (IPC).
[5] Regional patent filings and equivalents, Eurasian Patent Organization databases.
